NEW YORK - January 10, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors that purchased or otherwise acquired AstraZeneca securities, including the Company’s American Depositary Shares (“ADSs”), between February 23, 2022 and December 17, 2024 (the “Class Period”).
If you are an investor in AstraZeneca and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than February 21, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process.
On February 22, 2022, the start of the Class Period, AstraZeneca filed its Annual Report with the SEC, which included a risk disclosure that “[a]ny failure to comply with these [worldwide] applicable laws, rules and regulations may result in AstraZeneca being investigated by relevant governmental authorities. . . .”
On October 30, 2024, AstraZeneca posted an announcement on its website that Leon Wang, Executive Vice President International and AstraZeneca China President was under investigation by Chinese authorities.
On this news, the price of AstraZeneca ADSs fell $2.39 per share, or about 3.2%, to close at $72.83 per share on October 30, 2024.
On November 5, 2024, Yicai Global published an article reporting that “[d]ozens of senior executives at AstraZeneca China have been implicated in an ongoing insurance fraud case as of last week, according to a person familiar with the matter.”
On this news, the price of AstraZeneca ADSs fell $5.16 per share, about 7.2%, to close at $66.27 per share on November 5, 2024.
Then, on December 18, 2024, the Financial Times published an article entitled “AstraZeneca insiders expect sales dip in China after arrest of local boss,” reporting that AstraZeneca China President Leon Wang had been arrested.
On this news, the price of AstraZeneca ADSs fell $2.54 per share, about 3.8%, to close at $64.64 per share on December 18, 2024.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
CONTACT:
Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
View the original release on www.newmediawire.com
